Search Results

Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024.

Provectus Biopharmaceuticals, Inc. announced that its 2024 annual stockholder meeting, including meeting activities and a company update, will be accessible by Zoom Webinar.

Biopharmaceutical Market Outlook 2024-2032:

Eiger BioPharmaceuticals, Inc. today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30.

Bayer AG and Asklepios BioPharmaceutical, Inc. announced that the first patient has been randomized in GenePHIT, a Phase II trial of AB-1002 for the treatment of congestive heart failure.

KBI Biopharma, Inc., a JSR Life Sciences company and cGMP contract development and manufacturing organization, and Argonaut Manufacturing Services, Inc., a cGMP contract manufacturing organization serving the biopharmaceutical and diagnostics industries, announced a strategic alliance offering biopharmaceutical clients with end-to-end drug substance and drug product manufacturing solutions.

Navidea Biopharmaceuticals, Inc. announced that it filed a Form 15 with the Securities and Exchange Commission to deregister its common stock, preferred stock purchase rights and Series K preferred stock under Section 12 of the Securities Exchange Act of 1934, as amended, and to suspend its reporting obligations under Section 15 of the Exchange Act.

Provectus Biopharmaceuticals, Inc. today announced additions to its executive leadership team, reflecting Provectus’s dedication to enhancing shareholder value.